SWOG Chair Dr. Charles Blanke previews the SWOG spring 2016 meeting and 60th anniversary. Originally published on the SWOG Front Line April 1, 2016 – When we gather together in San Francisco at the end of this new month, we will kick off our 60th anniversary celebration. Big milestones invite reflection – on what we’ve done and …
Because answers to cancers come from clinical trials Since 1956, more than 200,000 participants have enrolled in SWOG-led studies; the resulting advancements in treatment and prevention have improved the lives of millions more. Why Cancer Clinical Trials? from The Hope Foundation on Vimeo. More about the group: SWOG has roughly 5,000 affiliated physician researchers – along …
Help us honor six decades of collaborative cancer research SWOG is a worldwide network of researchers that design and conduct cancer clinical trials. The Group’s goal is to change medical practice so it improves the lives of people with cancer. Since 1978, SWOG has held Group Meetings twice yearly to review progress, conduct Group business, and …
A SWOG trial shows bortezomib, lenalidomide, and dexamethasone delays recurrence and lengthens life for myeloma patients, indicating a possible new standard of care. [cta]View the Press Release[/cta] SWOG is a publicly funded worldwide network of researchers who design and conduct cancer clinical trials. The Group’s goal is to change medical practice so it improves the …
SWOG and The Hope Foundation pursue cancer research through collaboration, despite the fact that Group members, leadership and staff are based in locations all over the United States and beyond. Founded in 1993 by SWOG leaders, The Hope Foundation has granted more than $30 million in charitable funding to support the important work of the …
We are happy to announce the first round of awards from the new SWOG/Hope Foundation VA Integration Support Program. [cta]View the Press Release[/cta]
Two grants from The Hope Foundation’s SWOG Early Exploration and Development (SEED) Fund have been awarded to support the following projects: Siu Fun Wong, PharmD Chapman University School of Pharmacy “Formulation of Topical Vitamin K1 for Epidermal Growth Factor Receptor Inhibitors (EGFRIs)-Induced Skin Rash” The Vitamin K1 topical formulation developed from this proposal, if proven effective …
Click to enlarge.
Omar Aljitawi, MD, of the University of Kansas Cancer Center, has been researching a method to shorten the duration of neutropenia following stem cell transplantation, a standard-of-care procedure which accompanies high-dose chemotherapy for treatment of multiple blood cancers. Neutropenia invariably occurs following high-dose chemotherapy and resolves when the newly infused hematopoietic stem cells home to …
Three Hope Foundation grantees were announced at last week’s Spring 2015 SWOG Group Meeting in San Francisco. Following rigorous review processes, we are pleased to offer funding for the following research projects: SWOG/Hope Foundation Impact Award “Personalizing treatment for newly diagnosed AML using a novel ex vivo screen” Marc Loriaux, MD, PhD of Oregon Health & …
Michael LeBlanc, PhD
Group Statistician
JOIN OUR EMAIL LIST
Johanna Horn, President & CEO
